[Clinical and laboratory studies on SY5555 in pediatric infectious diseases]

Area of Science:

• Pediatric infectious diseases
• Pharmacology and pharmacokinetics
• Antimicrobial therapy

Background:

• Bacterial infections pose a significant health challenge in children.
• Novel antibiotics are crucial for combating resistant pathogens and improving treatment outcomes.
• Penem antibiotics offer a broad spectrum of activity against various bacterial strains.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of SY5555 dry syrup in pediatric patients.
• To assess the pharmacokinetic properties of SY5555 following oral administration in children.
• To determine the bacteriological eradication rates of SY5555 against common pediatric pathogens.

Main Methods:

• A clinical trial involving 20 children aged 8 months to 14 years with diverse bacterial infections.
• Administration of SY5555 dry syrup at varied doses (12.8–30.5 mg/kg/day) in three divided doses.
• Assessment of clinical outcomes, bacteriological eradication, adverse events, and in vivo pharmacokinetics.

Main Results:

• SY5555 achieved an overall clinical efficacy rate of 95.0% (19/20) across various infections including acute bronchitis, pharyngotonsillitis, and otitis media.
• High rates of bacterial eradication were observed for Staphylococcus aureus, Haemophilus influenzae, and other key pathogens.
• The drug was generally well-tolerated, with mild adverse events like diarrhea reported in one patient. Pharmacokinetic studies showed measurable plasma and urine concentrations.

Conclusions:

• SY5555 dry syrup is an effective and safe oral antibiotic for treating bacterial infections in children.
• The favorable efficacy and safety profile support its use in pediatric infectious disease management.
• Further research may explore its role in broader pediatric populations and against a wider range of pathogens.